Unlike broader-spectrum tyrosine kinase inhibitors, zungertinib is highly selective for HER2 and avoids targeting wild-type EGFR. This specific mechanism is crucial as it leads to a better toxicity profile, particularly reducing the common EGFR-related side effects of rash and diarrhea, improving patient tolerability.

Faced with the 'undruggable' switch two pocket in KRAS, Blossom Hill modifies the drug's properties rather than the protein target. By engineering a molecule with 'pseudo irreversible' characteristics, they create a long-lasting effect that compensates for the challenging binding pocket, thereby enhancing in-vivo efficacy.

By simultaneously targeting dozens of functionally unrelated survival genes across different chromosomes, Nuago's therapy makes it statistically improbable for cancer cells to mutate and develop escape routes. This multi-pronged attack from a single drug construct is a core advantage over therapies that cancer can evolve around.

By targeting MEK, which is downstream of RAS/RAF in the MAPK pathway, Immuneering's therapy can block a wider range of potential resistance mutations. This preempts the cancer's ability to adapt by mutating upstream proteins, a common failure point for drugs that target RAS directly.

While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.

Gene fusions create entirely new proteins, allowing for highly specific drug targeting with a wider therapeutic window and fewer side effects. In contrast, point mutations are subtle changes to existing proteins, making it difficult to inhibit the mutant form without affecting the wild-type, leading to lower efficacy and more toxicity.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.

A key strategy for Iterion is combining its Wnt-beta-catenin inhibitor with existing therapies like EGFR-TKIs. Research shows the Wnt pathway is often upregulated as a resistance mechanism to these primary treatments. By blocking this escape route, the combination therapy aims to prevent resistance and improve patient outcomes.

Blossom Hill is developing a 'switch two' allosteric pan-KRAS inhibitor. Unlike tri-complex molecules that block protein interaction but may not fully stop signaling, their approach 'rigidifies' the KRAS protein. This completely shuts down the signaling cycle, potentially offering superior durability and preventing the evolution of resistance.